![Alvin Shih](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Alvin Shih
Director/Board Member at
ZEVRA THERAPEUTICS, INC.
Net worth: 231 800 $ as of 2026-05-30
Profile
Alvin Shih is President, Chief Executive Officer & Director at Catamaran Bio, Inc. since 2021.
Dr. Shih is Chief Executive Officer & Director at Imbria Pharmaceuticals, Inc. starting 2025.
Dr. Shih is Independent Director at Oaktree Acquisition Corp.
III Life Sciences since 2024.
Dr. Shih is Independent Director at Zevra Therapeutics, Inc. since 2024.
Dr. Shih is Director at Rare-X.
Former roles include Chief Executive Officer at Disarm Therapeutics, Inc. from 2019 to 2020, Chief Executive Officer at Enzyvant Therapeutics, Inc. from 2016 to 2019, Executive Vice President-Research & Development at Travere Therapeutics, Inc. from 2015 to 2016, and Chief Operating Officer at Pfizer Inc. from 2010 to 2014.
Education includes undergraduate degree from Vanderbilt University, MBA from Kellogg School of Management, and doctorate from The University of Alabama School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-03 | 20,000 ( 0.03% ) | 231 800 $ | 2026-05-30 |
Alvin Shih active positions
| Companies | Position | Start |
|---|---|---|
| ZEVRA THERAPEUTICS, INC. | Director/Board Member | 2024-01-19 |
Rare-X
 Rare-X Packaged SoftwareTechnology Services Operates as a patient data processing platform | Director/Board Member | - |
Imbria Pharmaceuticals, Inc.
 Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | Chief Executive Officer | 2025-04-09 |
Catamaran Bio, Inc.
 Catamaran Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company developing allogeneic, off the shelf CAR-NK cell therapies for cancer treatment | Chief Executive Officer | 2021-01-31 |
Former positions of Alvin Shih
| Companies | Position | End |
|---|---|---|
Disarm Therapeutics, Inc.
 Disarm Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to treat patients with neurological diseases | Chief Executive Officer | 2020-11-30 |
Enzyvant Therapeutics, Inc.
 Enzyvant Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for treatment of rare diseases | Chief Executive Officer | 2019-01-31 |
| TRAVERE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2016-10-30 |
| PFIZER INC. | Chief Operating Officer | 2014-04-30 |
Catamaran Bio, Inc.
Catamaran Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company developing allogeneic, off the shelf CAR-NK cell therapies for cancer treatment | Chief Executive Officer | - |
Training of Alvin Shih
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
56
1st degree connections
11
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 11 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Zevra Therapeutics, Inc.
 Zevra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets proprietary prodrugs | Health Technology |
Vanderbilt University
 Vanderbilt University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Travere Therapeutics, Inc.
 Travere Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that engages in developing and delivering life-changing therapies to people living with rare kidney, liver & metabolic diseases | Health Technology |
Kellogg School of Management
 Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Alabama School of Medicine
 The University of Alabama School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to treat patients with neurological diseases | Health Technology |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | Commercial Services |
Catamaran Bio, Inc.
Catamaran Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company developing allogeneic, off the shelf CAR-NK cell therapies for cancer treatment | Health Technology |
Enzyvant Therapeutics, Inc.
Enzyvant Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for treatment of rare diseases | Health Technology |
Rare-X
Rare-X Packaged SoftwareTechnology Services Operates as a patient data processing platform | Technology Services |
- Stock Market
- Insiders
- Alvin Shih
Choose MarketScreener 
